[EN] QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA4BÊTA7
申请人:GILEAD SCIENCES INC
公开号:WO2020092375A1
公开(公告)日:2020-05-07
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
[EN] THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS<br/>[FR] DÉRIVÉS DE THIADIAZOLYLE COMME INHIBITEURS DE L'ADN POLYMÉRASE THÊTA
申请人:IDEAYA BIOSCIENCES INC
公开号:WO2020243459A1
公开(公告)日:2020-12-03
Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.
本文披露了某些噻二唑基衍生物 Formula (I):它们通过抑制 DNA 聚合酶 Θ(Polθ)活性来抑制 Polθ 活性,特别是通过抑制 Polθ 的 ATP 依赖螺旋酶结构域活性来抑制 Polθ 活性。此外,还披露了包括这些化合物的药物组合物以及治疗和/或预防通过抑制 Polθ 而可治疗的疾病的方法,如癌症,包括同源重组(HR)缺陷癌症。
[EN] HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE TGR5 POUR LE TRAITEMENT D'UNE MALADIE
申请人:KALYPSYS INC
公开号:WO2010016846A1
公开(公告)日:2010-02-11
The present invention relates to compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.
本发明涉及用作TGR5调节剂的化合物,以及用于治疗或预防代谢、心血管和炎症性疾病的方法。
OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF
申请人:AMGEN INC.
公开号:US20150045368A1
公开(公告)日:2015-02-12
Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.